BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 27871270)

  • 1. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
    Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
    BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study.
    Su SF; Hu YX; Ouyang WW; Lu B; Ma Z; Li QS; Li HQ; Geng YC
    BMC Cancer; 2013 Oct; 13():474. PubMed ID: 24118842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The survival outcomes and prognosis of stage IV non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy.
    Su S; Hu Y; Ouyang W; Ma Z; Lu B; Li Q; Li H; Wang Z; Wang Y
    Radiat Oncol; 2014 Dec; 9():290. PubMed ID: 25518882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer.
    Koshy M; Malik R; Mahmood U; Rusthoven CG; Sher DJ
    Pract Radiat Oncol; 2015; 5(6):374-82. PubMed ID: 26412340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy.
    Ouyang WW; Su SF; Ma Z; Hu YX; Lu B; Li QS; Geng YC; Li HQ
    Radiat Oncol; 2014 Jun; 9():147. PubMed ID: 24962716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
    Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
    J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
    Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
    Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
    BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study.
    Ouyang WW; Su SF; Hu YX; Lu B; Ma Z; Li QS; Li HQ; Geng YC
    BMC Cancer; 2014 Jul; 14():491. PubMed ID: 25001175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
    Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
    Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy.
    Sheu T; Heymach JV; Swisher SG; Rao G; Weinberg JS; Mehran R; McAleer MF; Liao Z; Aloia TA; Gomez DR
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):850-7. PubMed ID: 25216859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
    Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
    Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy.
    Zhou R; Xu T; Nguyen QN; Liu Y; Yang J; Komaki R; Gomez DR; Liao Z
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):452-461. PubMed ID: 29174428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
    Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
    Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer.
    Zhao L; West BT; Hayman JA; Lyons S; Cease K; Kong FM
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):103-10. PubMed ID: 17363189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.